News

Stay updated with our latest news and announcements. Check back regularly for updates on our projects, events, and more!

News

ICH Q11 drug substance development strategies

ICH Q11 development and manufacture of drug substances: analytical and process strategies for robust CMC principles implementation

Drug substance development sits at the foundation of every pharmaceutical program, yet it is often where the most...
ICH Q8 pharmaceutical development guideline

ICH Q8 guideline for pharmaceutical development: analytical strategies for quality by design in complex drug modalities

Regulatory expectations for pharmaceutical development have evolved considerably over the past two decades, from a compliance-driven and empirical...
Peptide purification methods in drug development

Peptide purification in drug development: methods, techniques, and analytical strategies

The growing pipeline of peptide-based therapeutics has placed peptide purification at the center of pharmaceutical manufacturing strategy. From...
metabolomics and lipidomics

Metabolomics and lipidomics in drug discovery and development: analytical approaches for biomarker discovery and preclinical research

The search for safer, more effective medicines increasingly depends on understanding how biological systems respond to disease, genetic...
Drug development planning

Drug development timeline: how early characterization prevents regulatory delays

The modern drug development timeline is highly shaped by manufacturing readiness, analytical understanding, and regulatory alignment. While innovation...
Chemistry, Manufacturing, and Controls (CMC) in the drug development process

Chemistry, Manufacturing, and Controls (CMC) in the drug development process: analytical strategies to support Investigational New Drug (IND) readiness and regulatory progression

The transition from discovery to clinical evaluation represents one of the most critical inflection points in the drug...
Analytical strategies for gene and cell therapy products

Analytical strategies for gene and cell therapy products: From characterization to regulatory expectations

The rapid expansion of advanced therapies has transformed how medicines are designed, manufactured, and evaluated. Unlike traditional pharmaceuticals,...
EMA’s nitrosamines guideline

EMA’s updated nitrosamines guideline: Implications for acceptable intake limits and analytical strategies

The landscape of impurity control in pharmaceutical manufacturing has been profoundly reshaped by the emergence of N-nitrosamines as...